On Nov. 8, Barr Pharmaceuticals (NYSE:BRL) released third-quarter earnings for the period ended Sept. 30.

  • Revenues for Q1 increased 7.1% to $332.4 million.
  • Contraceptive products, both generic and proprietary, continued to be drivers of sales growth for the company.
  • Operating and net margins declined considerably compared to last year, contributing to a significant decline in EPS.
  • The company is acquiring Pliva, and by doing so it will become the world's third-largest generic drug company, after Novartis (NYSE:NVS) and TevaPharmaceuticals (NASDAQ:TEVA).

(Figures in millions, except per-share data)

Income Statement Highlights

Q3 2006

Q3 2005

Change

Sales

$332.4

$310.4

7.1%

Net Profit

$52.8

$83.2

(36.6%)

EPS

$0.49

$0.78

(37.2%)

Diluted Shares

108.1

106.3

1.7%



Get back to basics with a look at the income statement.

Margin Checkup

Q3 2006

Q3 2005

Change*

Gross Margin

75.4%

74.2%

1.2

Operating Margin

34.1%

40.8%

(6.8)

Net Margin

15.9%

26.8%

(10.9)

*Expressed in percentage points

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets

Q3 2006

Q3 2005

Change

Cash + Invest.

$767.4

$763.6

0.5%

Accounts Rec.

$184.7

$167.8

10.1%

Inventory

$150.7

$128.6

17.2%



Liabilities

Q3 2006

Q3 2005

Change

Accounts Payable*

$186.8

$203.1

(8%)

Long-Term Debt

No Data

$20.6

No Data

*Includes accrued liabilities

Learn the ways of the balance sheet.

Cash Flow Highlights

Q3 2006

Q3 2005

Change

Cash From Ops.

$205.4

$84.4

143.4%

Capital Expenditures

$11.3

$15.9

(28.9%)

Free Cash Flow

$194.1

$68.5

183.4%



Find out why Fools always follow the money.

Related Companies:

  • Mylan Laboratories (NYSE:MYL)
  • Watson Pharmaceuticals (NYSE:WPI)
  • Par Pharmaceutical (NYSE:PRX)
  • Caraco Pharmaceutical Laborato (AMEX:CPD)

Related Foolishness:

How do you think Barr will do in the next few weeks? How about the next few years? Join CAPS, the Fool's new community-intelligence stock-rating service, and tell more than 12,000 fellow investors how you feel.

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.